Ovid Therapeutics Inc. Severance Costs
Ovid Therapeutics Inc. (OVID) reported Severance Costs of $209.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2026-08-13
- Ovid Therapeutics Inc. severance costs for the quarter ending 2026-06-30 was $209.00K.
- Ovid Therapeutics Inc. severance costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Ovid Therapeutics Inc. severance costs for the quarter ending 2025-12-31 was $400.00K.
- Ovid Therapeutics Inc. severance costs for the quarter ending 2025-09-30 was $47.00K, a 65.69% decline year-over-year.
- Ovid Therapeutics Inc. severance costs for fiscal 2025 was $882.00K, a 74.86% decline from fiscal 2024.
- Ovid Therapeutics Inc. severance costs for fiscal 2024 was $3.51M, a 112.22% increase from fiscal 2023.
- Ovid Therapeutics Inc. severance costs for fiscal 2023 was $1.65M.
| Period end | Severance Costs 1 month | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 9 month as first filed | Severance Costs 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $209.00K 10-Q · filed 2026-08-13 | $209.00K 10-Q · filed 2026-08-13 | $609.00K derived: sum of 3 quarters · filed 2026-08-13 | $656.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $400.00K derived: sum of 2 quarters · filed 2026-05-12 | $447.00K derived: sum of 3 quarters · filed 2026-05-12 | $447.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $447.00K derived: sum of 2 quarters · filed 2026-03-18 | $447.00K derived: sum of 3 quarters · filed 2026-08-13 | $882.00K 10-K · filed 2026-03-18 | ||
| 2025-09-30 | $47.00K 10-Q · filed 2025-11-12 | $47.00K derived: sum of 2 quarters · filed 2026-08-13 | $482.00K 10-Q · filed 2025-11-12 | $440.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | $435.00K 10-Q · filed 2026-08-13 | $393.00K derived: sum of 3 quarters · filed 2026-08-13 | $530.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $435.00K 10-Q · filed 2026-05-12 | $393.00K derived: sum of 2 quarters · filed 2026-05-12 | $530.00K derived: sum of 3 quarters · filed 2026-05-12 | $3.94M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $95.00K derived: sum of 2 quarters · filed 2026-03-18 | $3.51M derived: sum of 3 quarters · filed 2026-03-18 | $3.51M 10-K · filed 2026-03-18 | ||
| 2024-09-30 | $137.00K 10-Q · filed 2025-11-12 | $3.55M derived: sum of 2 quarters · filed 2025-11-12 | $3.55M 10-Q · filed 2025-11-12 | $3.70M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $3.40M 10-Q · filed 2024-08-13 | $3.41M 10-Q · filed 2025-08-13 | $3.41M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | |||||
| 2023-12-31 | $1.65M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |